文献速递核素与放射性配体治疗放射性药物与辐射防护

减少PSMA靶向小分子放射性药物唾液腺和肾脏摄取的简单策略

A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-01-25

该研究在PC3-PIP荷瘤裸鼠中评估加入冷PSMA-11对[177Lu]-PSMA-617生物分布的影响。1小时生物分布显示,加入500-2000 pmoles PSMA-11可大幅降低肾脏和唾液腺摄取,而肿瘤摄取未显著受影响,提示该方法有望减少非靶器官毒性。

要点

  • 加入500-2000 pmoles冷PSMA-11可大幅降低肾脏摄取。
  • 加入500-2000 pmoles冷PSMA-11可降低唾液腺摄取。
  • 肿瘤摄取未受显著影响,但高剂量组数值下降。

核心结论

  • 加入冷PSMA-11可大幅降低[177Lu]-PSMA-617在唾液腺和肾脏的摄取,且未显著影响肿瘤摄取。

研究设计与样本

  • 采用荷PC3-PIP(PSMA+)肿瘤的裸鼠,每组4只,给予[177Lu]-PSMA-617并分别加入0、5、100、500、1000和2000 pmoles PSMA-11,1小时后进行生物分布研究。

主要发现

  • 1小时肿瘤摄取(%ID/g)在加入0、5、100、500、1000和2000 pmoles PSMA-11时分别为21.71±6.13、18.7±2.03、26.44±2.94、16.21±3.5、13.52±3.68和12.03±1.96。
  • 1小时肾脏摄取(%ID/g)对应为123.14±52.52、132.31±47.4、84.29±78.25、2.12±1.88、1.16±0.36和0.64±0.23。
  • 1小时唾液腺摄取(%ID/g)对应为0.48±0.11、0.45±0.15、0.38±0.3、0.08±0.03、0.09±0.07和0.05±0.02。

临床怎么用

  • 在PSMA靶向放射性配体治疗中,可考虑加入冷PSMA-11以降低唾液腺和肾脏摄取,从而减少非靶器官毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Peptide-based prostate-specific membrane antigen (PSMA) targeted radionuclide therapy (TRT) agent [177Lu]-PSMA-617 has emerged as leading TRT candidate for treatment of castration-resistant prostate cancer (mCRPC). [177Lu]-PSMA-617 and other small molecule-based PSMA ligands have shown efficacy in reducing the tumor burden in mCRPC patients but irradiation to the salivary gland and kidneys is a concern and dose-limiting factor. Therefore, methods to reduce non-target organ toxicity are needed to safely treat patients and preserve their quality of life. Herein, we report that addition of cold PSMA ligand PSMA-11 can aid in reducing the uptake of [177Lu]-PSMA-617 in the salivary glands and kidneys. METHODS: Groups of athymic nude mice (n = 4) bearing PC3-PIP (PSMA+) tumor xenografts were administered with [177Lu]-PSMA-617 along with 0, 5, 100, 500, 1000, and 2000 pmoles of PSMA-11 and biodistribution studies were performed at 1 h. RESULTS: Biodistribution studies at 1 h post-administration revealed that [177Lu]-PSMA-617 uptake in PC3-PIP tumors was 21.71 ± 6.13, 18.7 ± 2.03, 26.44 ± 2.94, 16.21 ± 3.5, 13.52 ± 3.68, and 12.03 ± 1.96 %ID/g when 0, 5, 100, 500, 1000, and 2000 pmoles of PSMA-11 were added, respectively. Corresponding uptake values in kidney were 123.14 ± 52.52, 132.31 ± 47.4, 84.29 ± 78.25, 2.12 ± 1.88, 1.16 ± 0.36, and 0.64 ± 0.23 %ID/g, respectively. Corresponding salivary gland uptake values were 0.48 ± 0.11, 0.45 ± 0.15, 0.38 ± 0.3, 0.08 ± 0.03, 0.09 ± 0.07, and 0.05 ± 0.02 % ID/g, respectively. CONCLUSION: The uptake of [177Lu]-PSMA-617 in the salivary gland and kidney can be substantially reduced without significantly impacting tumor uptake by adding cold PSMA-11.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Kalidindi TM, Lee SG, Jou K, et al. A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2021. PMID: 33495926. doi:10.1007/s00259-020-05150-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。